相关实验视频
Updated: Jul 5, 2025

09:11
Retinal Pathophysiological Evaluation in a Rat Model
Published on: May 6, 2022
4.6K
关于索马托斯塔丁在糖尿病视网膜病变中的影响
Yanhong Fang1, Qionghua Wang1, Youjian Li2
1Department of Ophthalmology, Chongqing University Jiangjin Hospital, Chongqing, China.
Neural regeneration research
|January 16, 2024
概括
索马托斯塔丁 (神经保护性) 通过保护视网膜神经元,显示出治疗早期糖尿病视网膜病变的前景. 需要进一步的研究来优化其用于预防视力损失的使用.
科学领域:
- 眼科医生 眼科 眼科
- 神经科学是一个神经科学.
- 内分泌学 在内分泌学.
背景情况:
- 糖尿病视网膜病变 (DR) 涉及由于视网膜索马托斯坦素不足而导致的神经血管单元损伤.
- 早期的DR阶段显示索马托斯塔丁表达的下降,引发神经退行和微血管损伤.
研究的目的:
- 审查糖尿病视网膜病变 somatostatin治疗的进展情况.
- 确定DR中基于体静止素的疗法所面临的挑战和未来方向.
主要方法:
- 对2019年2月至2023年2月发表的研究进行系统审查.
- 分析PubMed和谷歌学者数据库的索马托斯他林和糖尿病视网膜病变研究.
主要成果:
- 索马托斯塔丁替代是一种有前途的策略,用于DR的视网膜神经退行.
- 局部索马托斯塔丁在患有先前视网膜功能障碍的患者中显示出神经保护作用 (EUROCONDOR试验).
- 索马托斯坦在试验中没有影响糖尿病视网膜病变的出现.
结论:
- 索马托斯塔丁恢复可能有利于早期视网膜病变的患者.
- 解决查,患者分层,相互作用和施用途径对于早期DR预防至关重要.
更多相关视频
相关概念视频
Diabetes Mellitus: Overview and Type I Subtype
2.6K
Diabetes mellitus is a chronic metabolic disorder characterized by high blood glucose levels due to inadequate insulin production, insulin resistance, or both. The condition affects millions worldwide and can significantly impact their health and quality of life.
Type 1 diabetes is an autoimmune disease in which the immune system mistakenly attacks and destroys the insulin-producing beta cells in the pancreas. As a result, the body is unable to produce sufficient insulin, and individuals with...
Type 1 diabetes is an autoimmune disease in which the immune system mistakenly attacks and destroys the insulin-producing beta cells in the pancreas. As a result, the body is unable to produce sufficient insulin, and individuals with...
2.6K
Diabetes Mellitus: Type 2 and Gestational
2.4K
Type 2 diabetes, characterized by insulin resistance, arises when the insulin receptors on cells lose responsiveness to insulin, diminishing the cell's capacity to take up glucose, resulting in elevated blood glucose levels. To receive a diagnosis of Type 2 diabetes, a series of blood glucose tests are necessary to assess whether the blood glucose falls within normal parameters. If the result is out of the normal range, a patient may be diagnosed as prediabetic or diabetic, depending on the...
2.4K
Pathophysiology of Diabetes
940
Diabetes mellitus is a chronic metabolic disorder characterized by hyperglycemia. The four categories of diabetes are type 1 diabetes, type 2 diabetes, other specific types of diabetes, and gestational diabetes.
Type 1 diabetes is characterized by autoimmune-mediated destruction of pancreatic β cells, with environmental factors potentially triggering this process in genetically susceptible individuals. Despite many not having a family history, certain genes increase susceptibility,...
Type 1 diabetes is characterized by autoimmune-mediated destruction of pancreatic β cells, with environmental factors potentially triggering this process in genetically susceptible individuals. Despite many not having a family history, certain genes increase susceptibility,...
940
Glucagon-like Receptor Agonists
325
Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
325
Dipeptidyl Peptidase 4 Inhibitors
188
Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a...
188
Oral Hypoglycemic Agents: Biguanides and Glitazones
204
Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood...
204

